PhaseRx, Inc. PZRXQ

PZRXQ Company Overview

PhaseRx, Inc. was a clinical-stage biotechnology company focused on the development of messenger RNA (mRNA) therapeutics for rare and inherited diseases. The company operated within the biotechnology and pharmaceutical research sectors, with an emphasis on non-viral intracellular delivery technologies designed to transport therapeutic mRNA into target cells. Its research platform centered on proprietary delivery systems intended to improve the stability and cellular uptake of mRNA-based medicines.

The company’s primary development efforts targeted metabolic and liver-associated disorders, particularly conditions where replacement of missing or defective proteins could potentially be addressed through mRNA therapeutics. PhaseRx became publicly traded under the ticker PZRX before later trading over-the-counter as PZRXQ following financial distress and bankruptcy-related proceedings. Public disclosures indicate the company remained largely pre-revenue, relying primarily on equity financing, research partnerships, and capital market activity to fund operations. Data regarding ongoing operations following its restructuring and delisting is inconclusive based on available public sources.